Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.38 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 4/20 | 0.36 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | PLK1 | P53350 | 2/20 | 0.36 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.35 |
| ▸ | SELP | P16109 | 1/20 | 0.35 |
| ▸ | SELE | P16581 | 1/20 | 0.35 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4494458 | 1.00 | NR1H4 (0.38) | NR1H4HPSEPPARDPPARGPPARA | |
| SCHEMBL4488882 | 0.93 | ROCK2 (0.41) | NR1H4RXFP1ROCK2 | |
| SCHEMBL4488877 | 0.93 | ROCK2 (0.41) | NR1H4RXFP1ROCK2 | |
| SCHEMBL4497346 | 0.93 | NR1H4 (0.38) | NR1H4HPSEPPARDPPARGPPARA | |
| SCHEMBL4497348 | 0.93 | NR1H4 (0.38) | NR1H4HPSEPPARDPPARGPPARA | |
| SCHEMBL4498958 | 0.92 | PLK1 (0.42) | NR1H4HPSEPPARDPPARGPPARA | |
| SCHEMBL227669 | 0.92 | HSPH1 (0.42) | NR1H4PPARDPPARGPPARAPLK1 | |
| SCHEMBL227668 | 0.92 | HSPH1 (0.42) | NR1H4PPARDPPARGPPARAPLK1 | |
| SCHEMBL4498955 | 0.92 | PLK1 (0.42) | NR1H4HPSEPPARDPPARGPPARA | |
| SCHEMBL4504446 | 0.91 | ACP1 (0.41) | PLK1ACP1RXFP1ROCK2PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | claimed |
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-03 | — | — | US | claimed |
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
| EP-1527046-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-05-04 | — | — | EP | disclosed |
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2004009546-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | NFATC1, ICOS, BET1 | NR1H4 665/4885HPSE 4604/4885PPARD 747/4885 |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | NR1H4 1011/4885HPSE 3850/4885PPARD 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.